Citius Pharmaceuticals shares are trading lower after the company received FDA Complete Response Letter for Lymphir (Denileukin Diftitox) for relapsed/refractory cutaneous T-cell lymphoma.
Portfolio Pulse from Benzinga Newsdesk
Citius Pharmaceuticals received a Complete Response Letter from the FDA for Lymphir (Denileukin Diftitox) for relapsed/refractory cutaneous T-cell lymphoma, causing its shares to trade lower.
July 31, 2023 | 9:39 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citius Pharmaceuticals' stock is trading lower due to the FDA's Complete Response Letter for Lymphir.
The FDA's Complete Response Letter is typically a form of regulatory setback, often leading to delays in drug approval. This negative news directly impacts Citius Pharmaceuticals, causing its stock to trade lower.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100